PRELIMINARY SCIENTIFIC PROGRAM
Last updated on May 31, 2024
✍️
Last updated on May 31, 2024 ✍️
Thursday, June 13, 2024
8:00 - 8:30 AM Welcome Coffee
8:30 AM - 8:40 AM Introduction on behalf of the scientific committee by Alexandre Mebazaa (Paris, FRA)
8:40 AM - 10:30 AM
Session 1: Cardiogenic Shock: Time for paradigm shift!
Moderated by Christopher O'Connor (Falls Church, USA) and Hannah Schaubroeck (Brussels, BEL)
Speakers (10 minutes each)
CS trials: a new approach is needed: Susanna Price (London, GBR)
Lessons from ECLS-Shock: Holger Thiele (Leipzig, GER)
Further lessons from DAN-GER: Jacob Møller (Odense, DEN)
Lessons from observational studies: Pascal Leprince (Paris, FRA)
Dealing with heteregoneity in care: Erin Bohula (Boston, USA)
Global networking is key: Navin Kapur (Boston, USA)
Toward personalized management!: Vanessa Blumer (Falls Church, USA)
Panel discussion
Moderated by Christopher O'Connor (Falls Church, USA) and Hannah Schaubroeck (Brussels, BEL)
Susanna Price (London, GBR), Holger Thiele (Leipzig, GER), Jacob Møller (Odense, DEN), Pascal Leprince (Paris, FRA), Erin Bohula (Boston, USA), Navin Kapur (Boston, USA), Vanessa Blumer (Falls Church, USA), Keith Aaronson (FDA, USA), Carlos Alviar (New York, USA), EMA, NIH/NHLBI
Paper: Vanessa Blumer (Falls Church, USA) & Connor O’Brien (San Francisco, USA)
10:30 - 10:50 AM Coffee Break
10:50 AM - 12:00 PM
Session 2: Cardiogenic Shock: Inflammation: a driver of outcome
Moderated by Janine Pöss (Leipzig, GER) & Jason Katz (New York, USA)
Speakers (10 minutes each)
Inflammation markers and Cardiogenic Shock phenotypes: Sabri Soussi (Toronto, CAN)
Genotyping: Alastair Proudfoot (London, GBR)
Phase 2 cardiac surgery trial design: Peter Pickkers (Nijmegen, NED)
New biomarkers (IL6 and DPP3): Florian Wenzl (Zürich, SUI)
DPP3 and vascular effect: Adrien Picod (Paris, FRA)
DOBERMANN trial: Helle Søholm (Copenhagen, DEN)
Panel discussion
Moderated by Janine Pöss (Leipzig, GER) & Jason Katz (New York, USA)
Sabri Soussi (Toronto, CAN), Alastair Proudfoot (London, GBR), Peter Pickkers (Nijmegen, NED), Florian Wenzl (Zürich, SUI), Adrien Picod (Paris, FRA), Helle Søholm (Copenhagen, DEN), EMA, NIH/NHLBI
Paper: Helle Søholm (Copenhagen, DEN) & Florian Wenzl (Zürich, SUI)
12:00 - 1:00 PM Lunch Break
1:00 PM - 3:20 PM
Session 3: Improve Cardiogenic Shock trial design to prevent neutral trial
Moderated by William O'Neill (Detroit, USA) and Susanna Price (London, GBR)
Speakers (10 minutes each)
We need positive trials: Rhonda Monroe (Charlotte, USA)
Randomization by patient is not appropriate: Alexandre Mebazaa (Paris, FRA)
Is clustering by center the answer?: Brian Cuthbertson (Toronto, CAN)
Control arm should remain "control": Rebecca Mathew (Ottawa, CAN)
From patient selection to choice of endpoints and to length of follow-up: Mahir Karakas (Hamburg, GER)
Post-device period is very important: Roberta Bogaev Chapman (Abiomed, USA)
SOC in a device trial: a challenge: Navin Kapur (Boston, USA)
Should we include cardiac arrest?: Uwe Zeymer (Ludwigshafen, GER)
Registry-based randomised trials: David Morrow (Boston, USA)
eCPR: Roberto Lorusso (Maastricht, NED)
Win Ratio in critical care: are we ready?: Harriette Van Spall (Hamilton, CAN)
Industry perspective: Nitin Salunke (Supira Medical, USA)
Panel discussion
Moderated by William O'Neill (Detroit, USA) and Susanna Price (London, GBR)
Rhonda Monroe (Charlotte, USA), Alexandre Mebazaa (Paris, FRA), Brian Cuthbertson (Toronto, CAN), Mahir Karakas (Hamburg, GER), Rebecca Mathew (Ottawa, CAN), Roberta Bogaev Chapman (Abiomed, USA), Navin Kapur (Boston, USA), Uwe Zeymer (Ludwigshafen, GER), David Morrow (Boston, USA), Jan Belohlavek (Prague, CZE), Roberto Lorusso (Maastricht, NED), Harriette Van Spall (Hamilton, CAN), Nitin Salunke (Supira Medical, USA), Chang Fu Wu (FDA,USA), Bram Zuckerman (FDA, USA), EMA, NIH/NHLBI
Paper: Antoine Kimmoun (Nancy, FRA)
3:20 - 3:40 PM Coffee Break
3:40 PM - 4:50 PM
Session 4: Ongoing studies
Moderated by Alessandro Sionis (Barcelona, ESP)
Discussants (5 minutes each)
DOREMI2: Rebecca Mathew (Ottawa, CAN)
RECOVER IV: William O'Neill (Detroit, USA)
Unload VA-ECMO + Impella: Dirk Westermann (Freiburg, GER)
Altshock-2: Alice Sacco (Milan, ITA)
ANCHOR: Alain Combes (Paris, FRA)
LevoHeartShock: Bruno Levy (Nancy, FRA)
CERAMICS: Mir Babar Basir (Detroit, USA)
IV-cangrelor STEMI shock: Sarah Gorgis (Cleveland, USA)
Continuous Cerebral Autoregulation Monitoring in ECMO Patients - a pilot study: Lucy Zhang (Falls Church, USA)
Pharmacologic Optimization of Mechanical Support in Cardiogenic Shock – A New Paradigm: Balimkiz Senman (Durham, USA)
Pilot Trials of Long-Term Subcutaneous EEG for Brain Monitoring in Cardiac Critical Illness: Laith Altaweel (Falls Church, USA)
Panel discussion
Moderated by Alessandro Sionis (Barcelona, ESP)
Rebecca Mathew (Ottawa, CAN), William O'Neill (Detroit, USA), Dirk Westermann (Freiburg, GER), Alice Sacco (Milan, ITA), Alain Combes (Paris, FRA), Bruno Levy (Nancy, FRA), Mir Babar Basir (Detroit, USA), Manreet Kanwar (Pittsburgh, USA), Sarah Gorgis (Cleveland, USA), Lucy Zhang (Falls Church, USA), Allen Waziri (iCE Neurosystems, USA), EMA, NIH/NHLBI
Paper: Mireia Padilla Lopez (Barcelona, ESP) & Francesca Manicone (Brussels, BEL)
4:50 - 5:00 PM Coffee Break
5:00 PM - 6:45 PM
Session 5: Positive trials in critical care: the key role of regulators
Moderated by Mona Fiuzat (Arlington, USA), Alexandre Mebazaa (Paris, FRA) and Rhonda Monroe (Charlotte, USA)
Discussants (5 minutes each)
Patient's Perspective: Rhonda Monroe (Charlotte, USA)
Investigator Perspective: EU: Thomas Lüscher (Zurich, SUI)
Investigator Perspective: US: Mitchell Krucoff (Durham, USA)
Investigator Perspective: Japan: Naoki Sato (Tokyo, JPN)
Scientific Press perspective: Stuart Spencer (The Lancet, USA)
Industry Perspective: Chuck Simonton (Abiomed, USA), Andres Beiras (Getinge, GER), Karine Bourgeois (4TEEN4, GER), Liesbeth Hof (AM-Pharma, NED)
Regulators' Perspective: Ileana Piña (Cleveland, USA)
Regulators' Perspective: FDA: Kathleen Grunder (FDA, USA) & Jordan Pomeroy (FDA, USA)
Regulators' Perspective: EMA: Maciej Kostrubiec (EMA, POL)
NIH Perspective: George Sopko (NHLBI, USA)
Panel discussion
Moderated by Mona Fiuzat (Arlington, USA), Alexandre Mebazaa (Paris, FRA) and Rhonda Monroe (Charlotte, USA)
David Baran (Fort Lauderdale, USA), Rhonda Monroe (Charlotte, USA), Thomas Lüscher (Zurich, SUI), Mitchell Krucoff (Durham, USA), Naoki Sato (Tokyo, JPN), Stuart Spencer (The Lancet, USA), Chuck Simonton (Abiomed, USA), Andres Beiras (Getinge, GER), Karine Bourgeois (4TEEN4, GER), Liesbeth Hof (AM-Pharma, NED), Ileana Piña (Cleveland, USA), Kathleen Grunder (FDA, USA), Jordan Pomeroy (FDA, USA), Maciej Kostrubiec (EMA, POL), George Sopko (NHLBI, USA), Mauro Moscucci (FDA, USA), David Baran (Fort Lauderdale, USA), EMA, NIH/NHLBI
Paper: TBD
6:45 PM - 7:00 PM
Take home messages: Susanna Price (London, UK) and Alexandre Mebazaa (Paris, FRA)
7:00 PM Adjourn & Dinner
Friday, June 14, 2024
8:00 - 8:30 AM Welcome Coffee
8:30 AM - 8:40 AM
Introduction on behalf of the scientific committee by Alexandre Mebazaa (Paris, FRA)
8:40 AM - 11:00 AM
Session 6: Acute Heart Failure: What trials are still needed?
Moderated by Ileana Piña (Cleveland, USA) and Sumeet Mitter (Falls Church, USA)
Speakers (10 minutes each)
Primary objectives in implementation RCTs: Harriette Van Spall (Hamilton, CAN)
STRONG-HF: Gad Cotter (Momentum Research, USA)
What trials I need for my daily practice? Christopher O’Connor (Falls Church, USA)
Combining effective oral therapies Alexandre Mebazaa (Paris, FRA)
How to assess combining GDMT and devices? Biykem Bozkurt (Houston, USA)
Concepts for ADHF Therapeutic Development Mona Fiuzat (Arlington, USA)
Role of nurses and APPs in implementing therapies: Carolyn Rosner (Falls Church, USA)
Worsening Heart Failure: how to improve implementation of heart therapies?: Annette Kent (FIRE1, USA)
Discussants (5 minutes each)
Industry perspective: Hela Ben Hamouda (Medtronic International, SUI) & Juuso Blomster (CardioSignal, FIN)
Patient's perspective: Rhonda Monroe (Charlotte, USA)
Panel discussion
Moderated by Ileana Piña (Cleveland, USA) and Christopher O’Connor (Falls Church, USA)
Harriette Van Spall (Hamilton, CAN), Gad Cotter (Momentum Research, USA), Christopher O’Connor (Falls Church, USA), Alexandre Mebazaa (Paris, FRA), Biykem Bozkurt (Houston, USA), Mona Fiuzat (Arlington, USA), Carolyn Rosner (Falls Church, USA), Annette Kent (FIRE1, USA), Hela Ben Hamouda (Medtronic International, SUI), Juuso Blomster (CardioSignal, FIN), Rhonda Monroe (Charlotte, USA), Andrew Farb, (FDA, USA), EMA, NIH/NHLBI
Paper: Mattia Arrigo (Zurich, SUI)
11:00 - 11:30 AM Coffee Break
11:00 AM - 1:00 PM
Session 7: Management of massive bleeding
Moderated by Sean Collins (Nashville, USA) and Wesley Self (Nashville, USA)
Speakers (10 minutes each)
Current global recommendations: Natalie Kreitzer (Cincinatti, USA)
Clinical considerations in hemorrhagic shock in the acute setting: Amelia Maiga (Nashville, USA)
Investigator’s perspective: Ashkan Shoamanesh (Toronto, CAN)
How to generate evidence to manage surgical hemorrhagic shock: Jennifer Gurney (Houston, USA)
Discussants (5 minutes each)
Industry perspective: Anna Sundgren (AstraZeneca, USA), George Sopko (NHLBI, USA)
Panel discussion
Moderated by Sean Collins (Nashville, USA) and Wesley Self (Nashville, USA)
Natalie Kreitzer (Cincinatti, USA), Amelia Maiga (Nashville, USA), Stuart Connolly (Toronto, CAN), Jennifer Gurney (Houston, USA), Martin Cowie (AstraZeneca, USA), George Sopko (NHLBI, USA), Tek Lamichhane (FDA, USA), George Gibeily (FDA, USA) EMA, NIH/NHLBI
Paper: Anaïs Caillard (Paris, FRA)
1:00 - 2:00 PM Lunch Break
2:00 - 4:30 PM
Session 8: Improving outcomes in the critically ill patients: AI and physicians working hand-in-hand
Moderated by Stephen Browning (FDA, USA) and Etienne Gayat (Paris, FRA)
Keynote lecture (20 minutes)
AI-based algorithms used in critical care: Romain Pirracchio (San Francisco, USA)
Speakers (10 minutes each)
AI in ICU: run or hug?: Etienne Gayat (Paris, FRA)
How can AI help research in my company?: Anna Sundgren (AstraZeneca, USA)
DEBATE - Impact of AI on scholarly publishing: Emma Grainger (The Lancet, GBR) & Romain Pirracchio (JAMA, USA)
Discussants (5 minutes each)
Regulatory Perspectives on Artificial Intelligence & Machine Learning: Stephen Browning (FDA, USA)
Industry perspective: Shan Jegatheeswaran (J&J)
How AI start-ups are improving critical care outcomes: Anis Ghorbel (Precisia Care, SUI), Danielle Bergman (JvionAI, USA), David Talby (johnsnowlabs.com), Quentin François (Previa Medical), Romy Benninga (Abionic), Subbu Venkatraman (Eko Health), Sebastian Herrmann (Siemens Advanta) & Adam Saltman (Namsa)
Panel discussion
Moderated by Stephen Browning (FDA, USA) and Etienne Gayat (Paris, FRA)
Romain Pirracchio (JAMA/San Francisco, USA), Anna Sundgren (AstraZeneca, USA), Emma Grainger (The Lancet, GBR), Stephen Browning (FDA, USA), Shan Jegatheeswaran (J&J), Christine Gouillard (Us2.ai, USA), Anis Ghorbel (Precisia Care, SUI), Danielle Bergman (JvionAI, USA), David Talby (johnsnowlabs.com), Quentin François (Previa Medical), Romy Benninga (Abionic), Subbu Venkatraman (Eko Health), Sebastian Herrmann (Siemens Advanta) & Adam Saltman (Namsa), EMA, NIH/NHLBI
Paper: Baptiste Vasey (Oxford, GBR)
4:30 - 5:00 PM Coffee Break
4:30 - 7:00 PM
Session 9: ARDS 2024 guidelines shape trial design
Moderated by Emma Grainger (The Lancet, GBR) & Christina Barkauskas (Durham, USA)
Speakers (10 minutes each)
New global definition of ARDS: Michael Matthay (San Francisco, USA)
Impact of the global definition on future trial design: Sarina Saheyta (San Francisco, USA)
What are the priorities for future clinical trialists: Maurizio Cecconi (Milan, ITA)
Ongoing large trials with ECMO: Alain Combes (Paris, FRA)
Lung Division’s support of ARDS, Pneumonia & Sepsis research: Guofei Zhou (NIH, USA)
C5A: a promising target in ARDS: Martin Witzenrath (Berlin, GER)
I-SPY ARDS platform trial design: Derek Russell (Birmingham, USA)
Discussants (5 minutes each)
Patient perspective: Eileen Rubin (Chicago, USA)
Industry perspective: Hollmann Aya (Getinge, GER), Axel Vater (Aptarion Biotech, GER) & Negin Hajizadeh (Bayer, USA)
Panel discussion
Moderated by Emma Grainger (The Lancet, GBR) & Christina Barkauskas (Durham, USA)
Michael Matthay (San Francisco, USA), Sarina Saheyta (San Francisco, USA), Maurizio Cecconi (Milan, ITA), Alain Combes (Paris, FRA), Guofei Zhou (NIH, USA), Martin Witzenrath (Berlin, GER), Derek Russell (Birmingham, USA), Eileen Rubin (Chicago, USA), Niels Riedemann (InflaRx, GER), Axel Vater (Aptarion Biotech, GER) & Negin Hajizadeh (Bayer, USA), Martin Staempfli (CSL Behring, GER), EMA, NIH/NHLBI
Paper: Sarina Saheyta (Baltimore, USA)
7:00 PM Adjourn
7:00 PM Cocktail & Dinner in the Embassy of France, Washington D.C.
Saturday, June 15, 2024
8:00 - 8:30 AM Welcome Coffee
8:30 - 8:35 AM Welcome introduction by Alexandre Mebazaa (Paris, FRA)
8:35 AM - 10:40 AM
Session 10: Sepsis I: Endotype-guided therapy
Moderated by Michelle Chew (Malmö, SWE) & Alexandre Mebazaa (Paris, FRA)
Speaker (10 minutes each)
Is biomarker-guided therapy ready for prime-time?: Bruno François (Limoges, FRA)
BOOST: Pierre-François Laterre (Brussels, BEL)
Septic shock i-Micro: Matthieu Legrand (San Francisco, USA)
Digital biomarkers for Sepsis trials: Nathan Shapiro (New Haven, USA)
Discussants (5 minutes each)
Industry perspective: John Orloff (Alexion, USA)
Industry Perspective: Martina Kalle-Brune (Adrenomed, GER), Margarita Salcedo (Inotrem, FRA), Jean-François Llitjos (BioMérieux, FRA), Yinong Zhou (Novartis, USA), Carlos López-Espina (Prenosis, USA) & Thomas Reimer (Bayer, GER), John Kellum (Spectral, USA)
Panel discussion
Moderated by Michelle Chew (Malmö, SWE) & Alexandre Mebazaa (Paris, FRA)
Bruno François (Limoges, FRA), Pierre-François Laterre (Brussels, BEL), Matthieu Legrand (San Francisco, USA), Nathan Shapiro (New Haven, USA), John Orloff (Alexion, USA), Martina Kalle-Brune (Adrenomed, GER), Margarita Salcedo (Inotrem, FRA), Jean-François Llitjos (BioMérieux, FRA), Yinong Zhou (Novartis, USA), Carlos López-Espina (Prenosis, USA) & Maria Borentain (Bayer, USA), John Kellum (Spectral, USA), Debra Foster (Spectral Medical, CAN), EMA, NIH/NHLBI
Paper: Adrien Picod (Paris, FRA)
10:40 AM - 11:00 AM Coffee Break
11:00 AM - 1:00 PM
Session 11: Sepsis II: Trialists and regulators: can we agree on an endpoint?
Moderated by Nathan Nielsen (Albuquerque, USA) & Diana Stanley (The Lancet, USA)
Speakers (10 minutes each)
Mortality is dead: Ashish Khanna (Winston-Salem, USA)
Change in sofa score: Pierre-François Laterre (Brussels, BEL)
Improvement in organ perfusion: François Dépret (Paris, FRA)
Organ dysfunction: Margarita Salcedo (Inotrem, FRA)
Lessons from 2024 European guidelines: Michelle Chew (Malmö, SWE)
Discussants (5 minutes each)
Patient's Perspective: Eileen Rubin (Chicago, USA)
Industry Perspective: Melanie Wosnitza (Bayer, GER)
Regulator's Perspective: EMA, FDA & PMDA
Panel discussion
Moderated by Nathan Nielsen (Albuquerque, USA) & Diana Stanley (The Lancet, USA)
Ashish Khanna (Winston-Salem, USA), TBD, François Dépret (Paris, FRA), Jean-Jacques Garaud (Inotrem, FRA), Michelle Chew (Malmö, SWE), Eileen Rubin (Chicago, USA), Maria Borentain (Bayer, USA), FDA, EMA, PMDA & NIH/NHLBI
1:00 PM Adjourn & Lunch
Please note: the program above is only indicative and is not yet confirmed. Speakers may be changed according to their availability.
For past editions’ scientific programs, click on the links below:
